After a brief introduction, Shernan Holtan, MD, and Haris Ali, MD, discuss the distinction between acute and chronic graft-vs-host disease.
Back
My Treatment Approach: Optimizing Treatment for Chronic GVHD
This educational program, led by experts Shernan Holtan, MD, and Haris Ali, MD, explores the latest strategies and emerging treatments for optimizing management of chronic graft-vs-host disease (cGVHD), including monitoring techniques, therapeutic options, and patient-reported outcomes.
My Treatment Approach: Optimizing Treatment for Chronic GVHD
Episodes
All
All
Medical experts discuss navigating chronic GVHD.
Medical experts discuss overall goals for cGVHD treatment as well as concerns with long-term corticosteroid use in treatment.
Medical experts discuss criteria for switching GVHD treatments and how to choose between available treatment options.
Medical experts discuss advanced therapies in cGVHD.
Medical experts discuss the data that led to belumosudil’s FDA approval.
Medical experts discuss considerations for third-line treatment in chronic GVHD.
Medical experts discuss treatment selection for a specific clinical scenario.
Medical experts discuss the recent updates presented at ASH 2023 and TANDEM 2024.
Medical experts discuss the mechanism of action within axatilimab.
Medical experts discuss emerging trends in chronic GVHD treatment.
Medical experts discuss the role of patient-reported outcomes in cGVHD.
Medical experts discuss multidisciplinary approaches to GVHD.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
3
Five Under 5: Top Oncology Videos for the Week of 8/9
4
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
5